CellFiber Launches Zeito™ Cell Encapsulation Systems in the U.S. and Japan

CellFiber, a developer of cell culture technologies for regenerative medicine, has launched two products in its Zeito™ series of cell encapsulation systems in the U.S. and Japan.

The Zeito™ systems use CellFiber's proprietary cell encapsulation technology, which encloses cells within tubular alginate hydrogel structures to provide a three-dimensional environment for cell culture. This approach is designed to support high-density cell expansion while maintaining cell viability and function.

The Zeito™ Lite System is designed for early-stage research and feasibility studies, allowing researchers to evaluate the technology with different cell types. The Zeito™ Plus System supports larger-scale cell manufacturing through automated cell fiber production and a closed, single-use process designed to reduce manual handling and contamination risks in GMP-oriented workflows.

Together, the systems support applications ranging from laboratory-scale research to manufacturing process development. By combining three-dimensional cell culture technology with automated, closed-system processing, CellFiber aims to lower the hurdles in cell therapy manufacturing by addressing scalability, process consistency, and contamination control.

About CellFiber:

Founded in 2015, CellFiber is at the forefront of cell mass cultivation solutions, driven by its revolutionary CellFiber™ technology. The company offers comprehensive solutions, from process development for various cell types to support spanning research to clinical studies for a wide range of purposes. They provide equipment provision with small-scale, bench-top CellFiber™ extruders for internal R&D purposes. CellFiber™ welcomes opportunities for joint research to co-develop culturing processes and offers licensing through a royalty-bearing model, making it accessible for transformative advancements. Explore the possibilities of CellFiber™ technology and revolutionize your cell cultivation experience.

Visit the website for more information: https://cellfiber.jp/en/

About Fast Track Initiative:

Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.

Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/